Insights into the Feasibility and Acceptability of a Mobile Insulin Titration Application in Clinical Practice and Its Effects on Diabetes Outcomes.

touchREV Endocrinol

niversity of Pittsburgh, Department of Medicine, Division of Endocrinology and Metabolism, Pittsburgh, PA, USA.

Published: April 2024

: Insulin therapy is most effective if patients learn how to properly adjust insulin to achieve glycaemic targets. There is a need for methods and tools that can assist these processes in clinical practice. The purpose of this feasibility study was to evaluate an approach to support insulin dose adjustment in individual patients using a mobile titration application (app). : A cohort of adults (N=36) with type 2 diabetes with suboptimal glycaemia who were starting basal insulin self-titration were trained by a diabetes care and education specialist to use a mobile titration app to guide adjusting insulin doses. Glycaemia, diabetes distress and patient and provider satisfaction were assessed during the first 3 months after initiating basal insulin titration using the mobile app. : Mean haemoglobin type A1c (HbA1c) was significantly reduced by an average of 2.1 ± 2.2% from baseline to 3 months (p<0.001). Diabetes distress significantly decreased from baseline to follow-up with scores going down (or improving) across all scales. Both patients and providers reported high levels of satisfaction and positive experiences. : The model offers a promising solution to streamline insulin dosage adjustments to achieve specific clinical and self-management goals with high expectations for long-term benefits and warrants further investigation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132646PMC
http://dx.doi.org/10.17925/EE.2024.20.1.10DOI Listing

Publication Analysis

Top Keywords

insulin titration
8
titration application
8
clinical practice
8
mobile titration
8
basal insulin
8
insulin
7
insights feasibility
4
feasibility acceptability
4
mobile
4
acceptability mobile
4

Similar Publications

Article Synopsis
  • Ongoing efforts aim to enhance glycemic control in type 1 diabetes, focusing on semaglutide as a potential adjunct to automated insulin delivery therapy in adults.
  • A randomized, double-blind crossover trial was conducted with 28 participants, where semaglutide or placebo was used, showing a significant increase in the time spent within the target glucose range by an average of 4.8 percentage points.
  • No severe complications like diabetic ketoacidosis or hypoglycemia were reported, indicating that semaglutide is a safe and effective option for improving blood sugar levels in this context.
View Article and Find Full Text PDF

Background And Aim: The progressive nature of type 2 diabetes often, in time, necessitates basal insulin therapy to achieve glycemic targets. However, despite standardized titration algorithms, many people remain poorly controlled after initiating insulin therapy, leading to suboptimal glycemic control and complications. Both healthcare professionals and people with type 2 diabetes have expressed the need for novel tools to aid in this process.

View Article and Find Full Text PDF

Expectations and Outcomes From Glucagon-Like Peptide-1 Receptor Agonists As Adjunct Treatment for Type 1 Diabetes - Case Presentations.

J Diabetes Sci Technol

December 2024

Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.

Background: Type 1 diabetes (T1D) is characterized by the autoimmune destruction of pancreatic beta cells, leading to lifelong insulin dependence. Despite advancements in insulin therapies and glucose monitoring, maintaining optimal blood glucose control remains challenging with common issues like weight gain and glucose variability. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), approved for type 2 diabetes and obesity, are being explored off-label for T1D.

View Article and Find Full Text PDF

Modeling the fasting blood glucose response to basal insulin adjustment in type 2 diabetes: An explainable machine learning approach on real-world data.

Int J Med Inform

December 2024

Department of Health Science and Technology, Aalborg University, Aalborg, Denmark; Data Science, Novo Nordisk A/S, Søborg, Denmark. Electronic address:

Introduction: Optimal basal insulin titration for people with type 2 diabetes is vital to effectively reducing the risk of complications. However, a sizeable proportion of people (30-50 %) remain in suboptimal glycemic control six months post-initiation of basal insulin. This indicates a clear need for novel titration methods that account for individual patient variability in real-world settings.

View Article and Find Full Text PDF

Introduction: ONWARDS 5 evaluated the effectiveness and safety of insulin icodec (icodec) titrated with a dosing guide app (icodec with app) versus once-daily insulin analogs in insulin-naive adults with type 2 diabetes. The insulin glargine U300 (glargine U300) stratum was too small to enable a robust post hoc efficacy comparison. Augmentation methodology was applied to increase the glargine U300 group size using real-world data (RWD), to facilitate efficacy comparisons of icodec with app versus glargine U300, and to demonstrate the potential of the augmentation methodology to strengthen underpowered treatment comparisons (AUGMENT study).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!